Dapansutrile Plus Pembrolizumab in Melanoma (DREAM) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if the combination of the drugs Dapansutrile and Pembrolizumab is a safe and effective treatment for people with melanoma that does not improve after PD-1 therapy.
Melanoma
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with stage 3 or stage 4 unresectable melanoma
- Did not respond to previous treatment with anti-PD1 therapy
For more information about who can join this study, please contact the study team at carol.wiggs@duke.edu.
What is Involved?
The study is divided into 2 periods: a screening period and a study dosing period.
If you choose to join the study, you will go through a screening period to see if you are eligible. During this period, you will:
- Have a physical exam
- Answer questionnaires
- Have blood draws
- Have imaging scans (X-Ray, MRI, CT, or PET)
- Have a tumor biopsy (only if we do not already have a sample from you)
If you are eligible to proceed to the study dosing period, you will:
You will receive the study drugs for up to 2 years unless you have unwanted side effects or the study doctor finds that you are not getting better.
Study Details
